News
Public · Published
BofA adds TMUS, REGN to Value 10 list, leaves Growth 10 untouched
Bank of America Securities added T-Mobile US and Regeneron Pharmaceuticals to its Value 10 portfolio for November, replacing AutoZone and U.S. Bancorp after their surprise ratings fell below five. The Growth 10 list was unchanged. The models select S&P 500 stocks with BofA Buy ratings and strong earnings-surprise scores, ranking them by projected earnings growth or trailing price-to-earnings multiples.
Published:
Updated:
What happened
Bank of America Securities added T-Mobile US and Regeneron Pharmaceuticals to its Value 10 portfolio for November, replacing AutoZone and U.S. Bancorp after their surprise ratings fell below five. The Growth 10 list was unchanged. The models select S&P 500 stocks with BofA Buy ratings and strong earnings-surprise scores, ranking them by projected earnings growth or trailing price-to-earnings multiples.
Confirmed
Global impact / market context
The rebalance links company inclusion to earnings-surprise scores and valuation: a lower score can remove a stock, while selection may attract investor attention. If investors act on the list, buying or selling could affect share demand, though the article reports no trades or price moves.
Analyst inference
Through October, Growth 10 beat its benchmark by 11.7 percentage points year to date, and Value 10 beat its index by 9.3 points. Both models also beat their S&P benchmarks over three, five, and ten years, but those past results do not establish future performance.
Confirmed
What to watch
- Check the next Bank of America update for changes to either list; continued inclusion could keep investor attention on the selected stocks, but would not prove trading or price effects. Analyst inference
- Watch for whether AutoZone and U.S. Bancorp’s earnings-surprise ratings rise back to five or more, the threshold the article says they fell below before removal. Analyst inference
- Compare later returns for each list with its benchmark; sustained outperformance could draw more investor interest, while weaker results could reduce the appeal of following the models. Analyst inference